← Back to Clinical Trials
Recruiting NCT04166266

NCT04166266 National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04166266
Status Recruiting
Phase
Sponsor ANRS, Emerging Infectious Diseases
Condition Hepatitis D, Chronic
Study Type OBSERVATIONAL
Enrollment 800 participants
Start Date 2020-02-19
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Blood draw for the laboratory assessment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 800 participants in total. It began in 2020-02-19 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a multicentre observational study with prospective and retrospective data collection and retrospective data collection and biological collection from patients with HBV/HDV co-infection.

Eligibility Criteria

Inclusion Criteria: * Age \> 18 years, * Presenting a chronic HDV infection (positive serology), * Who gave his written informed consent before any intervention and the day of inclusion at the latest, * Affiliated to Health Insurance or to the "Aide Médicale d'Etat" (request for exemption pending). Exclusion Criteria: * Patient participating in another biomedical research with an exclusion period ongoing at inclusion, * Vulnerable patient (minor, adults legally protected: under judicial protection, guardianship, or supervision, persons deprived of their liberty). * Patients with predictable difficulties of follow-up according to the investigator.

Contact & Investigator

Central Contact

COULIBALY Fatoumata

✉ fatoumata.coulibaly@anrs.fr

📞 0144236110

Principal Investigator

Fabien ZOULIM

STUDY DIRECTOR

Hôpital de la Croix-Rousse

Frequently Asked Questions

Who can join the NCT04166266 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatitis D, Chronic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04166266 currently recruiting?

Yes, NCT04166266 is actively recruiting participants. Contact the research team at fatoumata.coulibaly@anrs.fr for enrollment information.

Where is the NCT04166266 trial being conducted?

This trial is being conducted at Angers, France, Annecy, France, Bobigny, France, Bobigny, France and 11 additional locations.

Who is sponsoring the NCT04166266 clinical trial?

NCT04166266 is sponsored by ANRS, Emerging Infectious Diseases. The principal investigator is Fabien ZOULIM at Hôpital de la Croix-Rousse. The trial plans to enroll 800 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology